Government Handing Out Cash Bonuses to Drug Researchers Who Rush Through Regulatory Approvals

"My job as your commissioner is to be your advocate and to fight for you. If you don't like it, we can get rid of it, but usually everybody loves money. The reward for fast regulatory work will come in the form of a quarterly bonus, to be paid out to FDA staffers starting in August, based on weighted time savings, work quality and work complexity."

"Once the system goes live, the FDA will essentially be paying its drug reviewers to approve applications faster in order to receive a financial reward - a conflict of interest that will all but guarantee increased reliance on the agency's error-prone AI system. Never before in its history has the FDA paid staff according to speed or performance metrics, so there are likely to be some negative consequences."

The FDA announced a pilot program offering quarterly cash bonuses to drug reviewers who complete assignments faster than scheduled. Payments will be based on weighted time savings, work quality, and complexity. This marks the first time in FDA history that staff compensation is tied to speed or performance metrics. The initiative raises ethical concerns, as reviewers now have financial incentives to approve drug applications quickly, potentially increasing reliance on the agency's error-prone AI system. Distribution challenges exist given varying team sizes and auxiliary personnel involvement. This announcement follows significant workforce reductions of nearly 20 percent since 2025, driven by budget cuts from Health and Human Services leadership.

Read at Futurism